ANS pharmacology and pathophysiology Flashcards
how is phenylephrine metabolized
MAO
2 examples of mixed function alpha and beta agonists
labetalol
carvedilol
cholinergic agonists (3)
nicotine
bethanechol
physostigmine
direct vasodilators/nitrodilators (3)
nitroprusside, NTG, hydralazine
does PAP increase with phenylephrine
yes d/t pulmonary vasoconstriction and increase in venous return
in the event of a neo OD, what is the drug you give and the drug you AVOID
give: a2 antagonist such as phentolamine
avoid: beta antagonists- can cause pedema
elimination half life of clonidine
8 hours
elimination half life of dexmedetomidine
2 hours
MOA of clonidine
inhibits NE release causing vasodilation and diminishing sympathetic outflow, decreasing HR and BP
sedation via locus coeruleus
pain modification and analgesia via dorsal horn of SC
clinical uses for clonidine (3)
treating HTN
controlling opiate and nicotine withdrawal manifestations
dx of pheochromocytoma
isoproterenol and
airway resistance
metabolism
receptor binding
gtt dose
primary use
airway resistance: decreased
metabolism: COMT
receptor binding: B1>B2 (.015-.15mcg/kg/min)
primary use: drug pacing. less commonly used now
dobutamine and
airway resistance
metabolism
receptor binding
primary use
airway resistance: no change
metabolism: COMT
receptor binding: B1>B2>A1 (2-20mcg/min)
primary use: cardiogenic shock, stress test
epinephrine IV infusion dose
.01-.2mcg/kg/min
systemic effects of catecholamines include
NE receptors it effects
mostly A1 and B1, minimal B2
IV infusion dose of NE
.1-.22mcg/kg/min
NE is first line therapy in
distributive shock
isoproterenol is derived from
dopamine
short acting B2 agonist inhalers include (3)
albuterol
levalbuterol
terbutaline
long acting B2 agonist inhalers include (2)
salmeterol
formoterol
which adrenoreceptor agonist is metabolized by the liver
ephedrine
what is the alpha antagonist family of drugs usually used to treat (4)
HTN
HF
BPH
pheo
MOA of phenoxybenzaprine and use/route of admin
non selective non competitive alpha antagonist that blocks NE and epi, lowering PVR and BP
HR may increased d/t increase in free, unbound NE
almost exclusively used in pheo’s preop to decrease BP
PO!!
what terminates the clinical effect of phenoxybenzaprine
since its irreversible, only the synthesis of new receptors can terminate its effect